Prospective Postmarketing Surveillance of Acute Myocardial Infarction in New Users of Saxagliptin: A Population-Based Study.

Sengwee TohMarsha E ReichmanDavid J GrahamChristian HamppRongmei ZhangMelissa G ButlerAarthi IyerMalcolm RuckerMadelyn PimentelJack HamiltonSamuel LendleBruce H Firemannull null

Published in: Diabetes care (2017)

We did not find a higher AMI risk in saxagliptin users compared with users of other selected antihyperglycemic agents during the first 5 years after U.S. Food and Drug Administration approval of the drug.

Keyphrases

drug administration
acute myocardial infarction
percutaneous coronary intervention
left ventricular
public health
emergency department
coronary artery disease
climate change
human health
drug induced
adverse drug